Suppr超能文献

世界血浆分离协会注册处,2023 年更新。

The world apheresis association registry, 2023 update.

机构信息

Unit of Transfusion medicine of Sanquin Blood Supply, Sanquin Blood Supply Foundation in Amsterdam, the Netherlands.

Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

出版信息

Transfus Apher Sci. 2023 Dec;62(6):103831. doi: 10.1016/j.transci.2023.103831. Epub 2023 Oct 7.

Abstract

The WAA apheresis registry contains data on more than 140,000 apheresis procedures conducted in 12 different countries. The aim is to give an update of indications, type and number of procedures and adverse events (AEs). MATERIAL AND METHODS: The WAA-registry is used for registration of apheresis procedures and is free of charge. The responsible person for a center can apply at the site www.waa-registry.org RESULTS: Data includes reported AEs from 2012 and various procedures and diagnoses during the years 2018-2022; the latter in total from 27 centers registered a total of 9500 patients (41% women) that began therapeutic apheresis (TA) during the period. A total of 58,355 apheresis procedures were performed. The mean age was 50 years (range 0-94). The most common apheresis procedure was stem cell collection for which multiple myeloma was the most frequent diagnosis (51%). Donor cell collection was done in 14% and plasma exchange (PEX) in 28% of patients; In relation to all performed procedures PEX, using a centrifuge (35%) and LDL-apheresis (20%) were the most common. The main indication for PEX was TTP (17%). Peripheral veins were used in 56% as the vascular access. The preferred anticoagulant was ACD. AEs occurred in 2.7% of all procedures and were mostly mild (1%) and moderate 1.5% (needed supportive medication) and, only rarely, severe (0.15%). CONCLUSION: The data showed a wide range of indications and variability in apheresis procedures with low AE frequency.

摘要

WAA 单采登记处包含了在 12 个不同国家进行的超过 140000 次单采程序的数据。其目的是提供适应证、类型和数量以及不良事件(AE)的最新信息。

材料和方法

WAA 登记处用于登记单采程序,且免费使用。中心负责人可在 www.waa-registry.org 网站上申请。

结果

数据包括 2012 年报告的 AE 以及 2018-2022 年期间的各种程序和诊断;后者共有 27 个中心登记的共 9500 例患者(41%为女性)开始治疗性单采(TA)。共进行了 58355 次单采程序。平均年龄为 50 岁(范围 0-94 岁)。最常见的单采程序是用于采集干细胞,多发性骨髓瘤是最常见的诊断(51%)。14%的患者进行了供体细胞采集,28%的患者进行了血浆置换(PEX);与所有进行的程序相比,PEX 使用离心机(35%)和 LDL 单采(20%)最为常见。PEX 的主要适应证是 TTP(17%)。56%的患者采用外周静脉作为血管通路。首选的抗凝剂是 ACD。所有程序中有 2.7%发生了 AE,大多为轻度(1%)和中度(1.5%,需要支持性药物治疗),极少数为重度(0.15%)。

结论

数据显示了广泛的适应证和单采程序的变异性,AE 发生率低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验